More articles about: Cancer Research

Research on stopping Ewing sarcoma relapses through Michigan Medicine.

Retired businessman and Detroit Tigers fan Paul Hansen has created three planned gifts to support prostate cancer research, nursing scholarship support, and adult cerebral palsy research at Michigan Medicine.

Why many precursor lesions never develop into pancreatic cancer, according to findings from Michigan Medicine.

There has been little progress in understanding and treating liposarcoma due to its rarity and lack of research resources. In a new study, University of Michigan researchers have developed a novel mouse model that mirrors the disease in humans.

Maria Castro, Ph.D, of Michigan Medicine, received a prestigious $4.5M NIH grant that will help advance the understanding about deadly tumors and provide a path for developing new treatments.

Michigan Medicine findings suggest further investigation of FISH-negative tests for renal cell carcinoma could lead to more accurate diagnosis.

Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling.

Nonprofit organization Catching Up With Jack fuels leading-edge pediatric brain cancer research while honoring a journey of courage and faith.

Rogel Cancer Center researcher Steven J. Katz, M.D., M.P.H., on how genetic testing results impact both the cancer patient and their family.

Why smokers have a higher chance of developing pancreatic cancer and why they tend to have worse outcomes than nonsmokers, according to a new study by University of Michigan Health Rogel Cancer Center.

Zach Hiser, a testicular cancer patient, encourages fellow fans to get help if they have symptoms.

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 

A study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.